Nautic Partners Acquires QoL meds, LLC

Providence, RI

Nautic Partners, LLC today announced that it has partnered with management to acquire QoL meds, LLC (“QoL”). QoL is a leading specialty pharmacy serving the mental health community. QoL was founded in 2000 and is headquartered in Pittsburgh, PA.

QoL operates specialty pharmacies across the country and is focused on serving the needs of the mental health community. Dispensing over 2 million prescriptions and serving over 50,000 patients annually, QoL partners with mental health centers to integrate on-site pharmacy services in the delivery of care. QoL’s pharmacies support and complement the care model of the company’s clinical partners treating the severely mentally ill. In addition to medication dispensing, QoL offers a suite of value-added services including medication assistance and monitoring, outcomes and adherence reporting, customized packaging, patient education, assistance with reimbursement and clinical coordination, and 340b services. Over the last five years, QoL has grown from two pharmacies to 87 pharmacies as mental health centers have recognized the value of a pharmacy partner dedicated to serving mental health.

“QoL has developed into one of the largest and most well-respected specialty pharmacies by delivering unmatched quality of care to its patients and clinical partners. QoL’s business model and approach to the delivery of care appropriately balances all constituents of healthcare which is a critical component of our healthcare investing model at Nautic,” said Chris Crosby, Managing Director of Nautic. “We are excited to be partnering with Jim Smith and the entire QoL team and believe that the company is well positioned for continued growth.”

“We are thrilled to partner with Nautic who shares our vision of growth in building the leading provider of specialty pharmacies for the behavioral health community,” said Jim Smith, President and CEO, QoL meds. “Nautic brings a wealth of healthcare investing experience, and we look forward to partnering with them to continue our mission of improving the Quality of Life for people living with mental illness by establishing a higher level of prescriptive care.”

“QoL’s services enhance compliance, improve patient quality of care, and reduce healthcare costs,” continued Chris Corey, Principal of Nautic. “The market for mental health services is large and growing. With improved diagnosis of mental health disease, increased recognition by payers of active medication treatment protocols, and a continued shift to outpatient care delivery, we believe QoL is uniquely positioned to play an ever increasing role in delivering exceptional care to mentally ill patients and its clinical partners.”

QoL is Nautic Partners’ fourteenth investment from its most recent fund, Nautic Partners VI, L.P., and continues Nautic’s successful history of investing in the healthcare industry. Other representative Nautic healthcare investments include American Imaging Management, AXIA Health Management, Genova Diagnostics, Healthcare Payment Specialists, Medegen, Reliant Hospital Partners, Superior Vision and Theorem Clinical Research.

About QoL meds, LLC

QoL is a leading specialty pharmacy serving the mental health community. The Company operates 87 pharmacies nationwide. QoL was founded in 2000 and is headquartered in Pittsburgh, PA.

Certain statements about Nautic made by portfolio company executives herein are intended to illustrate Nautic’s business relationship with such persons, including with respect to Nautic’s facilities as a business partner, rather than Nautic’s capabilities or expertise with respect to investment advisory services. Portfolio company executives were not compensated in connection with their participation, although they generally receive compensation and investment opportunities in connection with their portfolio company roles, and in certain cases are also owners of portfolio company securities and/or investors in Nautic-sponsored vehicles. Such compensation and investments subject participants to potential conflicts of interest in making the statements herein.